Andrew Wei, MBBS, PhD

Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

A phase I trial was conducted to answer the question of whether targeting BCL-2 would be effective in AML.

Venetoclax was combined with low-dose chemotherapy to see whether the combination would raise response rates in relapsed/refractory patients. The combination was very well tolerated, with few severe side effects being reported.

Author | Andrew Wei, MBBS, PhD

Articles

Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AML